Company Team Search Site Map Careers Privacy Statement
:: Home
:: About Us
:: R&D
:: Products
:: Services
:: Infrastucture
:: Contact us
Virchow Products

Group History & Background

 

Parent organization of the company, the $400 million Virchow Group is a name to reckon with in the burgeoning active pharmaceutical ingredients (APIs) and drug intermediates business in India.

Founded in 1981, the Virchow Group today is the World's largest manufacturer of the antibacterial Sulfamethoxazole, while its other group company Saraca Laboratories Limited is the World's largest manufacturer of the anti ulcerant Ranitidine. Virchow Group produces and caters to 90% of the World's requirement of Sulfamethoxazole. Other group companies are leading manufacturers of the newer 2nd 3rd and 4th generation Cephalosporins and other specialty chemicals.


Virchow group has developed a good expertise in the process development of Pharmaceutical and biological products. Virchow Group is known for its strong background in chemical process engineering for scale up and backward integration of active pharmaceutical ingredients and for efficiently managing the down-stream operations involved in the production of various pharmaceutical products.

The Virchow group consists in all of 7 pharmaceutical manufacturing units and two Biotech setups. While all the units are WHO-GMP and ISO 9000:2001 Certified, the Group is also credited with the two US FDA approved sites. These sites and products have also been approved by Therapeutic Goods Administration, Australia (TGA) and by European Union’s Certificate of Suitability (COS)

Holistic perspective for total excellence

Environmental protection is an on-going process at all Virchow Group Companies and every employee is an active participant in this process of maintaining a clean and green environment. Virchow Group has the credit of being the first Active Pharmaceutical Ingredient (Bulk Drug) unit in India to receive Certification for compliance with ISO 14001 norms.

This certification demonstrates that Virchow's Environment Management System (EMS) complies with most stringent environmental standards at international levels.

News & Events

Virchow Biotech is filing for U.S.Food and Drug administration’s (FDA) approval for its in house developed advanced wound care products.

Virchow Biotech received Drug control’s (DCGI) approval for conducting clinical trials on periogen, an indigenously developed recombinant therapeutic product for periodontal diseases

Virchow Biotech and Ranbaxy signed an MOU to market Virchow’s indigenously developed recombinant therapeutic protein for osteoporosis treatment. We are the first in the world to launch this biogeneric product